Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2009 3
2010 1
2011 5
2012 3
2013 2
2014 2
2015 7
2016 6
2017 3
2018 1
2019 1
2020 1
2021 2
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Skoulidis F, et al. Among authors: giri u. Cancer Discov. 2015 Aug;5(8):860-77. doi: 10.1158/2159-8290.CD-14-1236. Epub 2015 Jun 11. Cancer Discov. 2015. PMID: 26069186 Free PMC article.
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. Byers LA, et al. Among authors: giri u. Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22. Clin Cancer Res. 2013. PMID: 23091115 Free PMC article.
Blasted cell line names.
Wang J, Byers LA, Yordy JS, Liu W, Shen L, Baggerly KA, Giri U, Myers JN, Ang KK, Story MD, Girard L, Minna JD, Heymach JV, Coombes KR. Wang J, et al. Among authors: giri u. Cancer Inform. 2010 Oct 14;9:251-5. doi: 10.4137/CIN.S5613. Cancer Inform. 2010. PMID: 21082038 Free PMC article.
Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado.
Galan-Cobo A, Stellrecht CM, Yilmaz E, Yang C, Qian Y, Qu X, Akhter I, Ayres ML, Fan Y, Tong P, Diao L, Ding J, Giri U, Gudikote J, Nilsson M, Wierda WG, Wang J, Skoulidis F, Minna JD, Gandhi V, Heymach JV. Galan-Cobo A, et al. Among authors: giri u. Mol Cancer Res. 2022 Feb;20(2):280-292. doi: 10.1158/1541-7786.MCR-21-0448. Epub 2021 Oct 15. Mol Cancer Res. 2022. PMID: 34654720 Free PMC article.
STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition.
Sitthideatphaiboon P, Galan-Cobo A, Negrao MV, Qu X, Poteete A, Zhang F, Liu DD, Lewis WE, Kemp HN, Lewis J, Rinsurongkawong W, Giri U, Lee JJ, Zhang J, Roth JA, Swisher S, Heymach JV. Sitthideatphaiboon P, et al. Among authors: giri u. Clin Cancer Res. 2021 Mar 15;27(6):1720-1733. doi: 10.1158/1078-0432.CCR-20-2859. Epub 2020 Dec 15. Clin Cancer Res. 2021. PMID: 33323404 Free PMC article.
Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy.
Soleimani M, Somma A, Kaoud T, Goyal R, Bustamante J, Wylie DC, Holay N, Looney A, Giri U, Triplett T, Dalby K, Kowalski J, Eckhardt SG, Van Den Berg C. Soleimani M, et al. Among authors: giri u. Mol Cancer Ther. 2022 Oct 7;21(10):1547-1560. doi: 10.1158/1535-7163.MCT-21-1044. Mol Cancer Ther. 2022. PMID: 35977156
Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy.
Holay N, Somma A, Duchow M, Soleimani M, Capasso A, Kottapalli S, Rios J, Giri U, Diamond J, Schreiber A, Piscopio AD, Van Den Berg C, Eckhardt SG, Triplett TA. Holay N, et al. Among authors: giri u. Front Immunol. 2023 Sep 6;14:1260545. doi: 10.3389/fimmu.2023.1260545. eCollection 2023. Front Immunol. 2023. PMID: 37744352 Free PMC article.
KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.
Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, Giri D, Cascone T, Kim JH, Ye Y, Multani AS, Chan CH, Erez B, Saigal B, Chung J, Lin HK, Wu X, Hung MC, Heymach JV, Lee MG. Wagner KW, et al. Among authors: giri u. J Clin Invest. 2013 Dec;123(12):5231-46. doi: 10.1172/JCI68642. Epub 2013 Nov 8. J Clin Invest. 2013. PMID: 24200691 Free PMC article.
34 results